Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Read Our Latest Stock Analysis on ETNB 89bio Trading Down 3.8 % Shares of ETNB opened at $8.31 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.66 and a quick ...

The publication, “A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH” reported that treatment with icosabutate demonstrated highly encouraging results in ...

These are some of the best-performing stocks in the health care sector over the past month Nathan Reiff has been writing expert articles and news about financial topics such as investing and ...

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

"One and one please love," a regular said, leaning on the counter at a pie and mash shop in London's East End. In seconds, one piping-hot beef pie appeared with a single scoop of mashed potatoes ...